Does a low hs-CRP, Lp-PLA2 activity, and myeloperoxidase profile suggest lower inflammation?

At age 52, low hs-CRP, Lp-PLA₂ activity, and MPO provide a coherent but indirect picture of relatively low inflammatory activity across acute-phase, lipid/macrophage-associated, and oxidative pathways. The overall interpretation is plausible with moderate confidence, but it is supportive rather than diagnostic.

Systemic and vascular inflammation

• hs-CRP carries the strongest meaning for systemic inflammation because it reflects cytokine-driven hepatic acute-phase signaling. It also showed a strong correlation with arterial ^18F-FDG-PET target-to-background ratio and independently predicted imaging-defined vascular inflammation in one cohort.
• Low MPO is compatible with reduced phagocyte oxidative activity, endothelial injury, and plaque inflammation; MPO had a modest independent positive association with carotid-plaque PET uptake.
• Lp-PLA₂ activity is biologically relevant to lipid-associated vascular inflammation, but its associations with PET-defined inflammation and incremental prognostic value have been inconsistent. Therefore, the three-test pattern cannot confirm low vascular inflammation or exclude focal residual arterial inflammation.

Vulnerable-plaque biology and mechanisms

• Higher hs-CRP has been associated with plaque progression, rupture, thin-cap fibroatheroma (TCFA), and myocardial-infarction risk in OCT-imaged stable coronary disease.
• Lp-PLA₂ is expressed in macrophages and necrotic cores of TCFAs and ruptured plaques; higher circulating levels have correlated with unstable presentations, thinner fibrous caps, and IVUS-defined vulnerable plaque. MPO adds mechanistic coherence through oxidative and macrophage-linked plaque progression, although direct TCFA evidence is less established.
• Concordantly low values therefore support a lower-probability inflammatory/vulnerable-plaque milieu, not absence of noncalcified plaque, TCFA, rupture, or future events.

Clinical interpretation

• ACC/AHA guidance recognizes hs-CRP ≥2.0 mg/L as a risk-enhancing factor in selected primary-prevention decisions; Lp-PLA₂ and MPO are not routine guideline-standard risk tests.
• Bottom line: This low three-marker profile reasonably supports lower systemic and vascular inflammatory activity and less active vulnerable-plaque biology, with hs-CRP providing most of the evidentiary weight. It should complement—not replace—clinical risk assessment and any indicated imaging.